share_log

RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $40

Benzinga ·  Apr 15 13:13

RBC Capital analyst Luca Issi maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and raises the price target from $35 to $40.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment